TABULA RASA HEALTHCARE INC (TRHC) Fundamental Analysis & Valuation
NASDAQ:TRHC • US8733791011
Current stock price
10.5 USD
+0.09 (+0.86%)
Last:
This TRHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TRHC Profitability Analysis
1.1 Basic Checks
- TRHC had negative earnings in the past year.
- In the past year TRHC has reported a negative cash flow from operations.
1.2 Ratios
- The Return On Assets of TRHC (-26.82%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-23.32%
ROA(5y)-18.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 23.61%, TRHC is doing worse than 83.72% of the companies in the same industry.
- TRHC's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for TRHC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.61%
2. TRHC Health Analysis
2.1 Basic Checks
- TRHC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for TRHC has been increased compared to 1 year ago.
- The debt/assets ratio for TRHC is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -0.66, we must say that TRHC is in the distress zone and has some risk of bankruptcy.
- TRHC has a Altman-Z score of -0.66. This is comparable to the rest of the industry: TRHC outperforms 44.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.66 |
ROIC/WACCN/A
WACC8.36%
2.3 Liquidity
- A Current Ratio of 1.57 indicates that TRHC should not have too much problems paying its short term obligations.
- The Current ratio of TRHC (1.57) is worse than 60.47% of its industry peers.
- TRHC has a Quick Ratio of 1.47. This is a normal value and indicates that TRHC is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.47, TRHC is doing worse than 60.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.47 |
3. TRHC Growth Analysis
3.1 Past
- TRHC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
- The Revenue has grown by 22.28% in the past year. This is a very strong growth!
- TRHC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.54% yearly.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112%
Revenue 1Y (TTM)22.28%
Revenue growth 3Y1.71%
Revenue growth 5Y17.54%
Sales Q2Q%24.02%
3.2 Future
- TRHC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.23% yearly.
- Based on estimates for the next years, TRHC will show a quite strong growth in Revenue. The Revenue will grow by 17.28% on average per year.
EPS Next Y94.12%
EPS Next 2Y52.76%
EPS Next 3Y34.23%
EPS Next 5YN/A
Revenue Next Year21.88%
Revenue Next 2Y18.38%
Revenue Next 3Y17.28%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. TRHC Valuation Analysis
4.1 Price/Earnings Ratio
- TRHC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- TRHC is valuated quite expensively with a Price/Forward Earnings ratio of 40.37.
- Based on the Price/Forward Earnings ratio, TRHC is valued a bit cheaper than the industry average as 74.42% of the companies are valued more expensively.
- TRHC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.24.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.37 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- TRHC's earnings are expected to grow with 34.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.76%
EPS Next 3Y34.23%
5. TRHC Dividend Analysis
5.1 Amount
- TRHC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRHC Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:TRHC (11/2/2023, 8:12:48 PM)
10.5
+0.09 (+0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07 2023-11-07/amc
Earnings (Next)03-04 2024-03-04/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners47.24%
Ins Owner Change0%
Market Cap284.02M
Revenue(TTM)338.12M
Net Income(TTM)-95.46M
Analysts48.89
Price Target10.71 (2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.51%
Min EPS beat(2)85.99%
Max EPS beat(2)125.03%
EPS beat(4)3
Avg EPS beat(4)27.01%
Min EPS beat(4)-127.59%
Max EPS beat(4)125.03%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.19%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)3.05%
Revenue beat(4)3
Avg Revenue beat(4)1.2%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)3.05%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)77.78%
EPS NY rev (1m)0%
EPS NY rev (3m)85.48%
Revenue NQ rev (1m)0.41%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.37 | ||
| P/S | 0.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.3
EYN/A
EPS(NY)0.26
Fwd EY2.48%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS12.5
BVpS-2.89
TBVpS-9.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.82% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 23.61% | ||
| FCFM | N/A |
ROA(3y)-23.32%
ROA(5y)-18.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.61%
F-Score2
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 77.37% | ||
| Cap/Sales | 5.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | -0.66 |
F-Score2
WACC8.36%
ROIC/WACCN/A
Cap/Depr(3y)72.04%
Cap/Depr(5y)69.33%
Cap/Sales(3y)10.17%
Cap/Sales(5y)8.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112%
EPS Next Y94.12%
EPS Next 2Y52.76%
EPS Next 3Y34.23%
EPS Next 5YN/A
Revenue 1Y (TTM)22.28%
Revenue growth 3Y1.71%
Revenue growth 5Y17.54%
Sales Q2Q%24.02%
Revenue Next Year21.88%
Revenue Next 2Y18.38%
Revenue Next 3Y17.28%
Revenue Next 5YN/A
EBIT growth 1Y-16.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year137.28%
EBIT Next 3Y39.09%
EBIT Next 5YN/A
FCF growth 1Y0.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-320.17%
OCF growth 3YN/A
OCF growth 5Y-16.67%
TABULA RASA HEALTHCARE INC / TRHC Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for TABULA RASA HEALTHCARE INC?
ChartMill assigns a fundamental rating of 2 / 10 to TRHC.
Can you provide the valuation status for TABULA RASA HEALTHCARE INC?
ChartMill assigns a valuation rating of 2 / 10 to TABULA RASA HEALTHCARE INC (TRHC). This can be considered as Overvalued.
Can you provide the profitability details for TABULA RASA HEALTHCARE INC?
TABULA RASA HEALTHCARE INC (TRHC) has a profitability rating of 1 / 10.
What is the expected EPS growth for TABULA RASA HEALTHCARE INC (TRHC) stock?
The Earnings per Share (EPS) of TABULA RASA HEALTHCARE INC (TRHC) is expected to grow by 94.12% in the next year.